253 related articles for article (PubMed ID: 8889906)
1. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Harvey AT; Preskorn SH
J Clin Psychopharmacol; 1996 Oct; 16(5):345-55. PubMed ID: 8889906
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
3. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
Gregor KJ; Way K; Young CH; James SP
J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
7. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
9. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann P; Rochat B
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions.
Preskorn SH
J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
[No Abstract] [Full Text] [Related]
12. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of drug-drug interactions: a goal of rational drug development.
Preskorn SH
J Clin Psychiatry; 1996; 57 Suppl 1():3-6. PubMed ID: 8617709
[No Abstract] [Full Text] [Related]
14. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
Spina E; Santoro V; D'Arrigo C
Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
[TBL] [Abstract][Full Text] [Related]
15. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.
Caraci F; Crupi R; Drago F; Spina E
Curr Drug Metab; 2011 Jul; 12(6):570-7. PubMed ID: 21395523
[TBL] [Abstract][Full Text] [Related]
16. Are pharmacokinetic drug interactions with the SSRIs an issue?
Brøsen K
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
[TBL] [Abstract][Full Text] [Related]
17. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
[TBL] [Abstract][Full Text] [Related]
18. Newer antidepressants and the cytochrome P450 system.
Nemeroff CB; DeVane CL; Pollock BG
Am J Psychiatry; 1996 Mar; 153(3):311-20. PubMed ID: 8610817
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Richelson E
Mayo Clin Proc; 1997 Sep; 72(9):835-47. PubMed ID: 9294531
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Hemeryck A; Belpaire FM
Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
